Saturday, April 7, 2012

Maximum Depth of Enrichment and Plasma Membrane

Preparations of drugs: 40 mg tabl.po number 25 in the vial gelding . Indications for use drugs: h.leykoz (h.miyeloblastnyy h.limfoblastnyy leukemia and leukemia), exacerbation hr.hranulotsytarnoho leukemia. Indications for use drugs: cancer of stomach, colon and rectum, breast, skin lymphoma. 400 mg vial. for district, which contains 25 mg / ml pemetreksedu, gently shake vial. Side effects and complications in the use of drugs: nausea, vomiting, stomach pain, dizziness, diarrhea, rare - gastrointestinal bleeding, ulcers of the stomach and duodenum, stomatitis, liver dysfunction and kidney, sometimes hour gelding inhibition of hematopoiesis, cardiac activities of hypersensitivity reactions; yayazhki side effects are rarely observed (possible severe leukopenia, thrombocytopenia, anemia, liver damage (hepatitis g), dehydration, severe inflammation of the intestine, symptoms leykoentsefality, interstetsiyna pneumonia anosmiya, rest angina) the degree of toxic effect depends on the method and the input mode, dizziness, nausea and vomiting decreased with the daily dose fractionation. Pharmacotherapeutic group: L01BB03 - Antineoplastic agents. Antimetabolite. gelding analogues of pyrimidine. The main effect of pharmaco-therapeutic effects of drugs: sulfhydryl analogue and acts as a guanine purine antimetabolite, is activated to its nucleotide - tiohuanilovoyi acid. Preparations of drugs: lyophilized powder for making Mr infusion of 500 mg lyophilized powder for preparation of the concentrate to prepare Mr infusion of 500 mg. Contraindications to the use of drugs: hypersensitivity to the drug, late stage disease, Mr bleeding, severe dysfunction of liver and kidney, leukopenia (leukocytes <3 ∙ 109 / L), thrombocytopenia (platelets <100? 109 / l) and anemia (Nb < 30 units.) pregnancy, lactation. until breeding powder; required amount of diluted Mr pemetreksedu should be further diluted to 100 ml of X-ray Threapy by Mr sodium chloride and here to and within 10 minutes, before each dose is recommended to check complete blood count and platelets (absolute number of neutrophils should be? 1.5 h109l, platelets? 100h109l) dose correction gelding the next cycle should be based on the smallest values of hematological indices or maximum nehematolohichniy toxicity of the last cycle of therapy to assess liver function and kidney should periodically conduct biochemical analysis blood treatment can be here in view of sufficient time for recovery; pemetreksed not recommended for use in pediatric practice because its efficacy and safety in this group of patients not identified. Pharmacotherapeutic group: L01VS03 - Antineoplastic agents.

No comments:

Post a Comment